Compare Inovio Pharmaceuticals Inc (INO) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Walmart Stores Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Walmart Stores Inc trades at $111.12 (market cap $892.90B). The key difference: Walmart Stores Inc is far larger — about 10002.2× Inovio Pharmaceuticals Inc's market cap, and Walmart Stores Inc pays a 0.88% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WMT | |
|---|---|---|
Market Cap | $89.27M | $892.90B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $134.20 |
52-Week Low | $1.05 | $95.67 |
Enterprise Value | $60.28M | $956.35B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Walmart (WMT) trades at $114.24, down 0.62% today, with a neutral technical signal and strong fundamentals including consistent earnings beats and robust cash flow. Revenue reached $681.0B in 2025 (source: company filings, 2025), with net income margin improving to 3.13%. Recent news highlights AI innovation and delivery expansion, while analyst consensus remains bullish with a $142.10 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include competitive pressure from Amazon and margin volatility. Wall Street's strong buy rating (72.72% of analysts) supports upside potential, though investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
